A new meta-analysis of studies from the Asia-Pacific region shows that Helicobacter pylori, a bacterium that can cause stomach ulcers and cancer, is becoming resistant to several common antibiotics. The analysis looked at how genetic mutations in the bacteria are linked to resistance.
Researchers found that resistance to clarithromycin, a key antibiotic, is driven by mutations called A2142G and A2143G, with resistance rates ranging from 19% to 34%. Metronidazole resistance was over 84% in East Asia, linked to rdxA mutations. Amoxicillin resistance, tied to pbp1A variants, ranged from 6% to 34%, and levofloxacin resistance, due to gyrA and gyrB mutations, was between 31% and 66%.
The study did not report on safety or side effects. A major limitation is the high variation among the studies included, which makes it hard to draw firm conclusions. The findings highlight the need for region-specific treatment guidelines and better diagnostic testing to choose the right antibiotics.
For patients, this means that standard treatments for H. pylori may not work as well in some parts of Asia. Doctors may need to test for resistance before prescribing antibiotics. This research does not change current practice immediately but underscores the importance of using antibiotics wisely.
